Drug Profile
Research programme: kRAS protein inhibitors - Tosk
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Tosk
- Class Antineoplastics
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Cancer in USA
- 13 Feb 2018 Tosk receives phase 2 of SBIR grant from National Cancer Institute for KRAS programme development in Cancer
- 04 Jan 2018 Preclinical trials in Cancer in USA (unspecified route) before January 2018